Adenocarcinoma of the pancreas is arguably the most challenging of human malignancies. Approximately 43 000 patients will be diagnosed with pancreatic cancer in the United States in 2010, and during this same period approximately 37 000 will die from this malignancy.1 About 15% to 20% of patients (6500-8600) diagnosed each year have localized disease that is amenable to potentially curative surgery.2 Despite such surgery, nearly 85% of patients are destined to experience relapse and die of their disease.3,4 Therefore, adjuvant therapy is an appealing therapeutic option designed to eradicate occult metastatic disease, delay disease recurrence, and enhance overall survival.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.